________________________________________________________________________________________________________________________________

(C) B2Bioworld 2013 Red Cross/Red Crescent, IFPMA, WHOPharma Boost for Red Cross/Red Crescent’s Community Disease Prevention Programme

March 2013. For the next two years the International Federation of Pharmaceutical Manufacturers Associations (IFPMA), an advocacy consortium of global pharma industry associations will support Red Cross/Red Crescent (IFRC) in its national community programmes for primary healthcare. These follow the UN initiative to mitigate or prevent non-communicable diseases. B2Bioworld has taken a closer look at the partnership, the framework and deliverables.

If you like to read this article, you can purchase it now

Please notice, when purchasing articles you agree to B2Bioworld's Terms and Conditions

Read Now - Please select your license (Prices incl. 7% VAT)

Article free of advertisement - 5 pages
- Includes data on total deaths broken down into broad cause group and regions (including Africa),
details on IFPMA membership 2013

Full Company License enquire here

Back to section

Related Editorial Articles

Merck: Getting closer to biosimilars markets in Asia and Latin America

Novo Nordisk: Doing our business a little bit differently than the others in industry
Mads Krogsgård-Thomsen, CSO of Novo Nordisk on Diabetes Treatments and Stem Cell R&D

WHO ECEH taps major donation and streamlines European operations

Roche Ethiopia: Build-up of an emerging market

FAO: Major shifts expected in operations
José Graziano da Silva, Director-General details his plans and unveils the approach to implementation

The Global Dimension of EU Health and Food Policies
Paola Testori-Coggi, former Director-General for Health and Consumers, European Commission

Metrics for Disease, Health, and Wellness
Personalized medicine? A systems look at human genetic diagnostics and the road ahead for next-generation sequencing by Leroy Hood, Institute for Systems Biology at Seattle